Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene

Journal of Molecular Medicine

Volumn 80, Issue 9, 2002, Pages 595-604

  Du, Ming ^a   Jones, Julie R ^b   Lanier, Jessica ^a   Keeling, Kim M ^a   Lindsey, Russell J ^c   Tousson, Albert ^e   Bebök, Zsuzsa ^d   Whitsett, Jeffrey A ^f   Dey, Chitta R ^f   Colledge, William H ^g   Evans, Martin J ^h   Sorscher, Eric J ^d   Bedwell, David M ^a,i  

^a University of California   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycoside; CFTR G542X transgene; Cystic fibrosis; Premature stop mutation

Indexed keywords

AMINOGLYCOSIDE; COMPLEMENTARY DNA; FATTY ACID BINDING PROTEIN; GENTAMICIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; ANTIINFECTIVE AGENT; CFTR PROTEIN, HUMAN; FORSKOLIN; MESSENGER RNA;

ALLELE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG EFFECT; ETHNIC GROUP; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; IMMUNOFLUORESCENCE; MEASUREMENT; MOUSE; NONHUMAN; PROMOTER REGION; STOP CODON; SURVIVAL; TRANSGENE; ACTION POTENTIAL; ANIMAL; BLOOD; EPITHELIUM CELL; GENE REPRESSION; GENETICS; HETEROZYGOTE; HUMAN; INTESTINE MUCOSA; METABOLISM; MOUSE MUTANT; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ACTION POTENTIALS; ANIMALS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; FORSKOLIN; GENE EXPRESSION; GENTAMICINS; HETEROZYGOTE; HUMANS; INTESTINAL MUCOSA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SUPPRESSION, GENETIC; TOBRAMYCIN; TRANSGENES;

EID: 0036379141     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-002-0363-1     Document Type: Article

References (27)

1. Consortium CFGA (1994) Population variation of common cystic fibrosis mutations. The Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat 4:167-177
2. Cutting GR (1996) Cystic fibrosis. In: Rimoin DL, Conner JM, Pyeritz RE (eds) Principles and practice of medical genetics. Churchill Livingstone, New York, pp 2685-2717
3. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH (1992) An animal model for cystic fibrosis made by gene targeting. Science 257:1083-1088
4. Ratcliff R, Evans MJ, Cuthbert AW, MacVinish LJ, Foster D, Anderson JR, Colledge WH (1993) Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet 4:35-41
5. Hasty P, O'Neal WK, Liu KQ, Morris AP, Bebok Z, Shumyatsky GB, Jilling T, Sorscher EJ, Bradley A, Beaudet AL (1995) Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene. Somat Cell Mol Genet 21:177-187
6. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstner J, Durie P, Nadeau J, Bear C, Tsui LC (1996) Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 12:280-287
7. Wilhelm JM, Jessop JJ, Pettitt SE (1978) Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells. Biochemistry 17:1149-1153
8. Phillips-Jones MK, Hill LS, Atkinson J, Martin R (1995) Context effects on misreading and suppression at UAG codons in human cells. Mol Cell Biol 15:6593-6600
9. Palmer E, Wilhelm JM (1978) Mistranslation in a eucaryotic organism. Cell 13:329-334
10. Manuvakhova M, Keeling K, Bedwell DM (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044-1055
11. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF (2000) Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 48:164-169
12. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ (1997) Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3:1280-1284
13. Howard M, Frizzell RA, Bedwell DM (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2:467-469
14. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA (1994) Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266:1705-1708
15. Ratcliff R, Evans MJ, Doran J, Wainwright BJ, Williamson R, Colledge WH (1992) Disruption of the cystic fibrosis transmembrane conductance regulator gene in embryonic stem cells by gene targeting. Transgenic Res 1:177-181
16. Dawson DC (1977) Na and Cl transport across the isolated turtle colon: parallel pathways for transmural ion movement. J Membr Biol 37:213-233
17. Grubb BR (1995) Ion transport across the jejunum in normal and cystic fibrosis mice. Am J Physiol 268:G505-513
18. Koerner TJ, Hill JE, Myers AM, Tzagoloff A (1991) High-expression vectors with multiple cloning sites for construction of trpE fusion genes: pATH vectors. Methods Enzymol 194:477-490
19. Davidson DJ, Rolfe M (2001) Mouse models of cystic fibrosis. Trends Genet 17:S29-37
20. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375-381
21. Keeling KM, Bedwell DM (2002) Clinically relevant amino-glycosides can suppress disease-associated premature stop mutations in theIDUA andP53 cDNAs in a mammalian translation system. J Mol Med (in press)
22. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860-865
23. Clancy JP, Ruiz F, Bebok Z, King C, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell D (2001) A pilot study of gentamicin treatment to suppress premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163:1683-1692
24. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R (1995) Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39:650-655
25. Dorin JR, Farley R, Webb S, Smith SN, Farini E, Delaney SJ, Wainwright BJ, Alton EW, Porteous DJ (1996) A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther 3:797-801
26. Rozmahel R, Gyomorey K, Plyte S, Nguyen V, Wilschanski M, Durie P, Bear CE, Tsui LC (1997) Incomplete rescue of cystic fibrosis transmembrane conductance regulator deficient mice by the human CFTR cDNA. Hum Mol Genet 6:1153-1162
27. Manson AL, Trezise AE, MacVinish LJ, Kasschau KD, Birchall N, Episkopou V, Vassaux G, Evans MJ, Colledge WH, Cuthbert AW, Huxley C (1997) Complementation of null CF mice with a human CFTR YAC transgene. EMBO J 16:4238-4249